-$0.03 Earnings Per Share Expected for BioScrip Inc (BIOS) This Quarter

Equities research analysts expect BioScrip Inc (NASDAQ:BIOS) to announce ($0.03) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for BioScrip’s earnings, with estimates ranging from ($0.04) to ($0.01). BioScrip posted earnings per share of ($0.15) in the same quarter last year, which suggests a positive year-over-year growth rate of 80%. The company is expected to report its next quarterly earnings results on Thursday, March 14th.

According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.33) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.31). For the next financial year, analysts forecast that the business will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.23) to ($0.14). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow BioScrip.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Tuesday, November 6th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $181.00 million during the quarter, compared to the consensus estimate of $171.35 million. During the same period last year, the firm earned ($0.12) earnings per share. BioScrip’s revenue for the quarter was down 8.9% on a year-over-year basis.

Several brokerages have recently weighed in on BIOS. BidaskClub raised BioScrip from a “hold” rating to a “buy” rating in a research report on Friday, January 11th. Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. TheStreet raised BioScrip from a “d+” rating to a “c-” rating in a research report on Monday, November 26th. Finally, Barrington Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of BioScrip in a research report on Friday, October 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $4.88.

Several large investors have recently added to or reduced their stakes in the stock. Venor Capital Management LP lifted its stake in shares of BioScrip by 0.3% in the third quarter. Venor Capital Management LP now owns 14,475,087 shares of the company’s stock worth $44,873,000 after acquiring an additional 50,000 shares in the last quarter. BlackRock Inc. lifted its stake in shares of BioScrip by 0.4% in the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after acquiring an additional 31,899 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of BioScrip by 0.5% in the third quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock worth $18,562,000 after acquiring an additional 27,904 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock worth $18,562,000 after acquiring an additional 27,904 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of BioScrip by 3.3% in the second quarter. FMR LLC now owns 5,593,200 shares of the company’s stock worth $16,388,000 after acquiring an additional 179,700 shares in the last quarter. Institutional investors and hedge funds own 82.09% of the company’s stock.

Shares of NASDAQ BIOS traded up $0.07 on Thursday, hitting $3.76. The company had a trading volume of 336,751 shares, compared to its average volume of 857,600. BioScrip has a 12-month low of $2.31 and a 12-month high of $4.14. The company has a market capitalization of $475.03 million, a price-to-earnings ratio of -8.55 and a beta of 0.61.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Article: How to Trade Using Analysts Ratings

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply